

January 3, 2022

Cabaletta Bio®

# Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference

PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present a pre-recorded company presentation at the H.C. Wainwright BioConnect Conference, which will become available for on-demand viewing on Monday, January 10, 2022 at 7:00 a.m. ET.

The pre-recorded presentation will be available on the News and Events section of the company's website at [www.cabalettabio.com](http://www.cabalettabio.com). Replays of the presentation will be available on the website for 90 days.

## About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta's proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The U.S. Food and Drug Administration (FDA) granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ([DesCAARTes™ Phase 1 Trial](http://www.cabalettabio.com/DesCAARTes)). The Company's MuSK-CAART product candidate is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit [www.cabalettabio.com](http://www.cabalettabio.com).

## Contacts:

Anup Marda  
Chief Financial Officer  
[investors@cabalettabio.com](mailto:investors@cabalettabio.com)

Sarah McCabe  
Stern Investor Relations, Inc.  
[sarah.mccabe@sternir.com](mailto:sarah.mccabe@sternir.com)

Cabaletta Bio<sup>®</sup>

Source: Cabaletta Bio